Alumis Shares Surge 16% as Traders Eye New Drug Move
Alumis soared 15.55% to $24.15 on double average volume after strong analyst support and late-stage psoriasis data, but remains a high-risk, loss-making biotech with no approved products; key investor focus is on Phase 2b lupus data due Q3 and a planned psoriasis NDA filing in Q4, with future stock moves hinging on these clinical and regulatory milestones.